Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | INPPL1 | O15357 | 3/20 | 0.40 |
| ▸ | INPP5A | Q14642 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | INPP5B | P32019 | 1/20 | 0.39 |
| ▸ | CDC25C | P30307 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294410 | 1.00 | CA1 (0.51) | CA1CA2ALDH1A1CES2CES1 | |
| SCHEMBL6294409 | 0.88 | ALDH1A1 (0.48) | CA1CA2ALDH1A1CES2CES1 | |
| SCHEMBL7064128 | 0.81 | CA1 (0.61) | CA1CA2ALDH1A1CES2CES1 | |
| SCHEMBL13980850 | 0.80 | CA1 (0.56) | CA1CA2ALDH1A1CES2CES1 | |
| SCHEMBL6041202 | 0.78 | CA1 (0.57) | CA1CA2ALDH1A1CES2CES1 | |
| SCHEMBL6041195 | 0.78 | CA1 (0.57) | CA1CA2ALDH1A1CES2CES1 | |
| SCHEMBL1525906 | 0.78 | CA1 (0.53) | CA1CA2ALDH1A1CES2CES1 | |
| SCHEMBL901296 | 0.78 | CA1 (0.53) | CA1CA2ALDH1A1CES2CES1 | |
| SCHEMBL4816746 | 0.77 | CA1 (0.56) | CA1CA2ALDH1A1CES2CES1 | |
| SCHEMBL4823831 | 0.77 | CA1 (0.56) | CA1CA2ALDH1A1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867197-B1 | Method of targeting conjugate molecules to mitochondria | MITOKOR (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030087858-A1 | Diagnostic and therapeutic compositions for alzheimer's disease | MITOKOR (US) | 2003-05-08 | — | — | US | disclosed |
| US-6171859-B1 | DEFECTIVE CYTOCHROME C OXIDASE; DIAGNOSING ALZHEIMER*S DISEASE | MITOKOR | 2001-01-09 | — | — | US | disclosed |
| US-6146831-A | CYBRID CELL LINE OF CULTURED CELLS HAVING GENOMIC AND MITOCHONDRIAL NUCLEIC ACIDS OF DIFFERENT BIOLOGICAL ORIGINS; FOR DRUG SCREENING AND EVALUATION OF THERAPY | MITOKOR (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0751951-A4 | DIAGNOSIS, THERAPY AND CELLULAR AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH MITOCHONDRIAL DEFECTS | MITOKOR (US) | 2000-05-03 | — | — | EP | disclosed |
| EP-0939832-A1 | MITOCHONDRIAL DNA MUTATIONS THAT SEGREGATE WITH LATE ONSET DIABETES MELLITUS | Mitokor (US) | 1999-09-08 | — | — | EP | disclosed |
| US-5840493-A | DIAGNOSIS OF LATE ONSET DIABETES BY DETECTION OF MUTATIONS IN ADENOSINE TRIPHOSPHATE SYNTHASE OR TRANSFER RNA (LYS) GENES IN A BIOLOGICAL SAMPLE; LABELLED NUCLEOTIDE SEQUENCES AS DETECTORS; ACCURACY | MITOKOR (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1998017826-A1 | MITOCHONDRIAL DNA MUTATIONS THAT SEGREGATE WITH LATE ONSET DIABETES MELLITUS | MITOKOR (US) | 1998-04-30 | — | — | WO | disclosed |
| EP-0751951-A1 | DIAGNOSIS, THERAPY AND CELLULAR AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH MITOCHONDRIAL DEFECTS | Mitokor (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995026973-A1 | DIAGNOSIS, THERAPY AND CELLULAR AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH MITOCHONDRIAL DEFECTS | MITOKOR (US) | 1995-10-12 | — | — | WO | disclosed |
| EP-0272330-B1 | 1,1,2-TRIARYL-1-BUTENE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1991-05-22 | — | — | EP | disclosed |
| US-4897503-A | ANTITUMOR AGENTS; TREATING MAMMARY CANCER AND ANOVULATORY INFERTILITY | TAIHO PHARMACEUTICAL (JP) | 1990-01-30 | — | — | US | disclosed |
| EP-0272330-A1 | 1,1,2-TRIARYL-1-BUTENE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087858-A1 | Diagnostic and therapeutic compositions for alzheimer's disease | COX5A, MT-CO3, COX6A1 | CA1 543/4885CA2 772/4885ALDH1A1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.